Oxcia is happy about all productive meetings and insightful discussions with pharma and investors at the LSX Nordic Congress. If you missed the congress and want to learn more about Oxcia and our exciting projects, please get in touch or schedule a meeting at the Nordic Life Science days in Malmö.
Latest news
-
New peer-reviewed article in Biomolecules, enforces the cancer cell selective killing of OXC-101. In a recently published article, Oxcia and its collaborators at Karolinska institute, shows that OXC-101 is extra efficacious in cancer cells overexpressing c-Myc (Hendriksson et al, Biomolecules… Continue reading New article enforces the cancer cell selective killing of OXC-101
-
Oxcia’s CEO Ulrika Warpman Berglund will attend the DDR Inhibitors Summit in Boston January 24-26th and present a poster describing the unique dual mechanism of action of OXC-101 and its potent and well tolerated anti-cancer effects. DDR is short for… Continue reading Oxcia attends DDR Inhibitors Summit in Boston
-
Tredje kvartalet (juli-september 2022) Rörelseresultatet uppgick till -10 927 043 (-3 573 590) SEK. Periodens resultat uppgick till -10 927 043 (-3 578 876) SEK. Kassaflödet från den löpande verksamheten uppgick till -4 612 924 (-2 749 079) SEK. Resultat per aktie före utspädning uppgick till -0,51… Continue reading Oxcia AB publicerar sin delårsrapport för tredje kvartalet 2022